![]() |
|
|
Vol. 289, Issue 3, 1634-1640, June 1999
Is Inhibited by Dexamethasone, Salicylate, and
N-Acetylcysteine in Synovial Fibroblasts1
Louis-Charles Simard Research Centre, Centre Hospitalier de L'Université de Montréal Campus Notre-Dame, and Department of Medicine, University of Montreal, Montreal, Quebec, Canada (I.M., W.Q.L., S.S., M.Z.); and Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia (M.A.)
| |
Abstract |
|---|
|
|
|---|
Proinflammatory cytokines, altered connective tissue metabolism, and
overexpression of matrix metalloproteinases (MMPs) such as stromelysin
compared to tissue inhibitors of metalloproteinases (TIMPs) result in
synovial inflammation and erosion of arthritic cartilage. Tumor
necrosis factor
(TNF-
) is a major synovial inflammatory mediator
responsible for inhibiting extracellular matrix (ECM) synthesis and
stimulating degradation of cartilage ECM by activated MMPs in arthritic
joints. To suppress these effects and to gain insight into the
mechanism of TNF-
action, we identified the inhibitors of TNF-
stimulation of stromelysin gene expression. In bovine synovial
fibroblasts, TNF-
did not affect a recently identified inhibitor,
TIMP-3, but induced stromelysin mRNA expression in a dose- and
time-dependent fashion (3- to 5-fold) which required de novo protein
synthesis. Stimulation by TNF-
was potently inhibited (99-100%) by
the synthetic glucocorticoid, dexamethasone. Sodium salicylate
dose-dependently inhibited (100%) the TNF-
action. Indomethacin and
ibuprofen were partially inhibitory. Free radical scavenger
antioxidant, N-acetylcysteine (but not other
antioxidants) also suppressed the TNF-
induction (36-100%) of
stromelysin suggesting involvement of reactive oxygen species in the
induction process. TNF-
induction of stromelysin gene expression can
therefore be inhibited at the gene expression level by several
pharmacological agents which are likely to function via arachidonic
acid metabolites, free radical scavenging or interference with the
activator protein 1, polyoma virus enhancer A-binding protein 3, and
nuclear factor
B classes of transcription factors. Our results may
help to elucidate the mechanism of TNF-
action and explain the
beneficial role of these agents in the treatment of inflammatory diseases.
| |
Introduction |
|---|
|
|
|---|
Tumor
necrosis factor
(TNF-
) is the major inflammatory mediator in
arthritis that invokes multiple responses and regulates numerous genes
implicated in inflammation (Vilcek and Lee, 1991
). It is found at high
levels in the synovial fluids of patients with arthritis, whose
synovium exhibits different degrees of inflammation (Westacott and
Sharif, 1996
). TNF-
inhibits transcription of cartilage-specific
type-II, -IX and -XI collagens in human chondrocytes and contributes to
cartilage loss in joint diseases (Reginato et al., 1993
).
Osteoarthritic (OA) cartilage is more susceptible to stimulation by
TNF-
due to increased p55 TNF-
receptor on the chondrocytes
(Westacott and Sharif, 1996
). TNF-
inhibits embryonal chondrocytic
phenotype and turns them into fibroblast-like cells in vitro
(Mohamed-Ali, 1995
). Overall, TNF-
promotes tissue destruction by
metalloenzymes and prevents tissue repair.
Matrix metalloproteinases (MMPs) consist of collagenases, stromelysins,
gelatinases, and membrane-type MMPs, which can degrade extracellular
matrix during its physiological (e.g., animal development) and
pathological (arthritis, cancer, cardiovascular diseases) turnover.
Activity of MMPs is regulated by the tissue inhibitor of
metalloproteinase (TIMP) gene family which consists
of four members named TIMP-1, -2, -3,
and -4 (Birkedal-Hansen, 1995
). MMPs not only
cause erosion of arthritic joints but also process TNF-
into its
mature secreted active form (Gearing et al., 1994
). Inhibitors of MMPs
prevent this processing. Stromelysin is a major MMP, responsible for
degradation of cartilage aggrecan and activation of procollagenase
(Birkedal-Hansen, 1995
). The expression of this gene is increased in
arthritic joints (Zafarullah et al., 1993
) and in unstable
atherosclerotic plaques (Galis et al., 1994
). Since synovial
inflammation is the major discomfort in arthritis, and the synovial
fibroblasts are the main target cell-type, this study was aimed at
identifying inhibitors of stromelysin upregulation by TNF-
in the
bovine synovial fibroblast model in order to understand the mechanism
of TNF-
action. We tested the hypothesis that the inhibitors of
protein synthesis, transcription factors, and reactive oxygen species
may block TNF-
stimulation of stromelysin gene expression.
| |
Materials and Methods |
|---|
|
|
|---|
Reagents.
Dulbecco's modified Eagle's medium (DMEM), fetal
calf serum (FCS), antibiotic-antimycotic agents, and agarose were
obtained from Canadian Life Technologies Inc. (Gibco-BRL, Burlington,
Ontario, Canada). Plastiware such as 100-mm plates and T-75 flasks were purchased from Nunc, Inc. (Roskilde, Denmark). Tumor necrosis factor
was obtained from R&D systems (Minneapolis, MN) and Boehringer Mannheim (Laval, Quebec). Cycloheximide was obtained from U.S. Biochemical Corporation (Cleveland, OH). Collagenase type II, dexamethasone, sodium salicylate, N-acetylcysteine,
indomethacin, ibuprofen,
N-methyl-L-arginine,
-tocopherol,
ascorbic acid, and pyrrolidine dithiocarbamate were purchased from
Sigma Chemical Company (St. Louis, MO). Digoxigenin (DIG) RNA labeling
and chemiluminescence systems were obtained from Boehringer
Mannheim. Hybond nylon membrane was purchased from Amersham Canada. RNA
probe labeling kits were obtained from Promega (Madison, WI).
Restriction endonucleases were purchased from Pharmacia Biotech. Inc.
(Baie d'urfé, Quebec, Canada). Other common laboratory reagents
were purchased from Fisher Scientific (Montreal, Canada).
Synovial Fibroblast Culture. Normal bovine synovial membranes were dissected from the freshly slaughtered adult animals from a local abattoir. The tissues were washed extensively in large volumes of 0.9% NaCl containing 5× antibiotic-antimycotic solution and further washed five times with PBS containing 5× penicillin-streptomycin and 1× fungizone (Gibco-BRL, Burlington, Ontario, Canada). Synovial fibroblasts were released by dissociation with trypsin and collagenase (Sigma type II) for 6 h in DMEM at 37°C. The cells were collected by centrifugation and washed three times with PBS and plated as primary monolayer cultures until adherence and confluent growth were attained. These cells were passaged several times to obtain a homogeneous population of synovial fibroblasts. Before different treatments, cells were kept in 0.5 or 5% serum containing DMEM for 24 h and then exposed to different reagents in the same medium for various periods of time described in the text.
RNA Extraction and Northern Blot Hybridization Analysis.
Total RNA was extracted by a rapid procedure (Chomczynski and Sacchi,
1987
) and aliquots of 5 µg were analyzed by electrophoretic fractionation in 1.2% formaldehyde-agarose gels. The integrity and
quantity of applied RNA were verified by ethidium bromide staining of
the gels and photography of the 28S and 18S ribosomal RNA bands. The
RNA was electroblotted onto Hybond nylon membrane using a Bio-Rad
Transblot in the presence of 1× standard saline citrate buffer
at a current of 500 mAmp for 12 h. Complete transfer was
ascertained by ethidium bromide staining of the gel. Northern blots
were hybridized as described previously (Zafarullah et al., 1993
) with
a human stromelysin cDNA probe generously provided by Dr. Richard
Breathnach (Muller et al., 1988
). This probe which cross-hybridizes
with bovine stromelysin RNA, was a 1.6-kbp
EcoRI-EcoRI cDNA fragment cloned in the plasmid
pGEM-4Z (Promega Biotec, Madison, WI). The vector was linearized with
NarI and RNA probe synthesized with T7 polymerase according
to the protocols of Promega Biotec. The bovine TIMP-3 probe (Su et al.,
1996
) was a 2.042-kbp EcoRI-EcoRI cDNA fragment
cloned in the plasmid pGEM-4Z (Promega Biotec). The vector was
linearized with SacI and the RNA probe was synthesized with
SP6 polymerase according to the protocols of Promega Biotec. The
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probe (from
American Type Culture Collection, Rockville, MD) was described earlier
(Zafarullah et al., 1993
). The human 28S ribosomal RNA plasmid
(American Type Culture Collection) was digested with XbaI and a probe was synthesized using T7 polymerase. The probes were labeled with the digoxigenin (DIG) RNA labeling kit containing DIG-11-UTP followed by prehybridization, hybridization, and detection of Northern blots with the DIG Luminescent Detection kit of Boehringer Mannheim according to their protocols. Alternatively the probes were
labeled to high-specific activity (1 × 108
cpm/µg) with [
-P32]CTP (3000 Ci/mmol;
DuPont-NEN (Boston, MA). Densitometric values from three
experiments (obtained with Alpha Imager, Canberra-Packard, Meriden, CT)
of stromelysin bands were divided by those of GAPDH bands to get an
average quantitative estimate of inhibition as depicted by bar graphs.
| |
Results |
|---|
|
|
|---|
Before testing the potential inhibitors, we investigated whether
the normal bovine synovial fibroblasts were responsive to TNF-
. To
that end, these cells were exposed for 24 h to different concentrations (50-1000 U/ml) of TNF-
in medium containing either minimal 0.5% or 5% FCS. The RNA was hybridized with a human
stromelysin probe which cross-hybridizes with the bovine stromelysin
mRNA of the same size. Although the lower doses were effective,
following normalization with the constitutive GAPDH or 28S control RNA, stromelysin mRNA was 3- to 4-fold inducible by TNF-
at 200 U/ml and
150 U/ml in 0.5% FCS and 4- to 5-fold inducible in 5% FCS (Fig.
1). The RNA levels of a housekeeping
GAPDH gene (Fig. 1, lower panel) and those of another
control gene, 28S rRNA (not shown), were not changed by the treatments.
Therefore, TNF-
is a potent inducer of stromelysin gene expression
in bovine synovial fibroblasts.
|
To determine the time course of stromelysin mRNA expression, cells were
treated with TNF-
(150 U/ml) for different time periods under 0.5%
FCS (Fig. 2A) or 5% FCS (Fig. 2B). Cells
were also treated for 16 h at a higher dose (1000 U/ml) as a
positive control. As shown in Fig. 2A, the maximal (3.4-fold) induction
of stromelysin mRNA expression occurred between 16 and 24 h. The
pattern of induction was similar under 5% FCS conditions
(2.5-3.75-fold), although overall levels of RNA were some what lower
than those under 0.5% conditions. To investigate the inducibility of a
recently characterized metalloproteinase inhibitor, TIMP-3, by TNF-
,
the same blots were hybridized with the bovine TIMP-3 cDNA probe. This
factor had very little effect on TIMP-3 gene expression
(middle panels of Fig. 2). The application of RNA in different lanes
was even. The RNA levels of GAPDH (Fig. 2, lower panel) and those of
28S rRNA (not shown) were not changed by the treatments. Therefore, TNF-
induces stromelysin but not TIMP-3 gene expression. These time
points were considered adequate for further inhibitor experiments.
|
The mechanism of TNF-
induction of stromelysin gene expression was
investigated by treatment of synovial fibroblasts with a nontoxic dose
(10 µg/ml) of an inhibitor of protein synthesis, cycloheximide. The
representative Fig. 3 demonstrates that
this treatment inhibited stromelysin induction by TNF-
.
Densitometric scanning of the stromelysin RNA levels normalized with
the GAPDH control RNA from three separate experiments revealed an
average inhibition of 100%.
|
To examine the effect of antiinflammatory corticosteroids on the
induction of stromelysin expression, cells were treated with a
synthetic glucocorticoid, dexamethasone (1-2 µg/ml). In three separate experiments, this agent potently suppressed (99-100%) stromelysin induction by TNF-
, reducing its mRNA to basal level (Fig. 4). GAPDH RNA levels were not
inhibited.
|
Aspirin-like agents or salicylates are commonly used drugs to treat
inflammation in arthritis. They can induce heat shock transcription
factor and inhibit TNF-
-induced nuclear factor
B (NF-
B)
activation (see Discussion). We examined whether this drug
influenced the induction of stromelysin gene by TNF-
. Cells were
treated with sodium salicylate (2-20 mM) alone or in combination with
TNF-
. It dose-dependently down-regulated TNF-
induction of
stromelysin gene expression in three separate experiments (Fig. 5, upper panel). Following correction
with the consistent GAPDH control RNAs, 100% inhibition was observed
(Fig. 5, lower panel).
|
Since glucocorticoids and salicylates can influence prostaglandin
metabolism, we further examined the latter's involvement by exposing
cells to other cyclooxygenase inhibitors, indomethacin and ibuprofen
alone or with TNF-
. Indomethacin and ibuprofen partially inhibited
(48-50%) stromelysin RNA induction by TNF-
in a reproducible
fashion (Fig. 6). Since nitric oxide (NO)
activates stromelysin, and salicylates can inhibit inducible nitric
oxide synthase (iNOS), we examined whether iNOS inhibitor could reduce TNF-
-induced stromelysin induction.
N-methyl-L-arginine (NMA), an
inhibitor of iNOS did not decrease but further increased this induction
(1 mM). Thus, arachidonic acid metabolites (but not NO) appear to
partially mediate this induction in our system.
|
To investigate the role of reactive oxygen species in TNF-
induction
of stromelysin gene, synovial fibroblasts were treated either with
TNF-
or with a thiolic antioxidant, N-acetylcysteine (NAC) alone or in combination. GAPDH and 28S RNA (not shown) levels were unaffected by the treatments. In three experiments, this agent, at
concentrations of 20 to 30 mM, strongly down-regulated stromelysin mRNA
induction by TNF-
in a dose-dependent fashion as depicted in the
representative Fig. 7 (upper panel). An
inhibition of 36% (at 10 mM) to 100% (at 20-30 mM) was observed with
NAC (Fig. 7, lower panel). Other antioxidants such as
-tocopherol, ascorbate, and pyrrolidine dithiocarbamate (PDTC) did
not block TNF-
induction of stromelysin. PDTC by itself induced
stromelysin mRNA and actually further enhanced induction by TNF-
(Fig. 8).
|
|
| |
Discussion |
|---|
|
|
|---|
In this report, we demonstrated that the proinflammatory cytokine,
TNF-
, up-regulates stromelysin gene without affecting TIMP-3 gene expression in mammalian synovial fibroblasts.
The induction process requires de novo protein synthesis and may
involve activation of transcription factors. We further showed that the induction can be inhibited or down-regulated by dexamethasone, an
aspirin-like drug and an antioxidant, possibly via inhibition of
arachidonic acid metabolites, antioxidant activity, and interference with the activator protein 1 (AP-1) and NF-
B classes of
transcription factors.
The demonstrated stromelysin gene induction by TNF-
in bovine
synovial fibroblasts is in agreement with other cell types where
stromelysin was inducible by this factor. In bovine nasal chondrocytes,
TNF-
induced both proteinases and prostaglandin E2 (Smith et al., 1992
). This factor
transcriptionally induced collagenase and stromelysin expression in
porcine chondrocytes by mediation of staurosporine- and H7-sensitive
protein kinases distinct from protein kinase C (Mitchell and Cheung,
1993
). The two major cell types in joints are clearly the targets of
TNF-
action.
A lack of TIMP-3 mRNA induction by TNF-
observed here is in contrast
with a previous report where TNF-
induced TIMP-3 expression in mouse
cells in the presence of 5% FCS serum (Sun et al., 1995
). In our
cells, TIMP-3 mRNA could not be markedly induced in the presence of 5%
or 0.5% serum with different brands of TNF-
. The lack of TIMP-3
induction by TNF-
is in accord with another study were TIMP-1
(another family member) was not induced but was suppressed by this
agent in synovial cells (Shingu et al., 1993
). MMP induction and TIMPs
inhibition (or noninduction) by TNF-
can contribute to
enzyme-inhibitor imbalance commonly observed in arthritic tissues (Dean
et al., 1989
).
Suppression of TNF-
induction of stromelysin by cycloheximide is
similar to that of collagenase inhibition by this agent in human
fibroblasts (Sciavolino et al., 1994
). Therefore, up-regulation is
through indirect mechanisms. The prolonged induction of the c-jun protooncogene by TNF-
was proposed as one of the
intermediate transcription factors that is part of the AP-1 complex
comprising of c-fos/c-jun factors. This occurs by upstream prolonged
activation of c-jun kinase which phosphorylates the transactivation
domain of c-Jun (Westwick et al., 1994
). The promoter DNA-binding
activities of AP-1 proteins are increased by TNF-
(Sciavolino et
al., 1994
). AP-1 binding sites are found in the human collagenase and
stromelysin 1 promoters (Buttice et al., 1991
). Contrary to a previous
report, we did not observe induction of stromelysin by cycloheximide
alone (Otani et al., 1990
) in bovine cells.
The inhibition of TNF-
action by the anti-inflammatory
glucocorticoid in synovial fibroblasts is particularly relevant to arthritis as synovial inflammation is a major discomfort for the patients, and glucocorticoids are used to relieve the symptoms in
patients and in animal models of arthritis. These agents stop further
erosion of cartilage in vivo by metalloproteinases (Pelletier et al.,
1994
). Inhibition of collagenase and stromelysin mRNA by dex was also
observed in human diploid FS-4 fibroblasts (Sciavolino et al., 1994
).
We showed that TIMP-3 gene induction by transforming growth factor
is also inhibited by dexamethasone (Su et al., 1996
). The molecular
mechanism of inhibition possibly involves direct interaction between
c-jun and glucocorticoid receptor proteins resulting in prevention of
c-jun binding to the AP-1 sequences in stromelysin promoter (Yang-Yen
et al., 1990
). Another recently proposed mechanism of immunosuppressive
and anti-inflammatory action of glucocorticoids is the induction of
IkB
gene product which associates with TNF-
-activated
NF-
B (dissociated NF-
B from IkB
) factor, thus preventing its
translocation to the nucleus (Scheinman et al., 1995
). The
applicability of this model for stromelysin inhibition is possible,
since NF-
B sites were detected in certain MMP promoters but not in
the known stromelysin promoters. An alternative mechanism of
suppression by dex could be due to its ability to down-regulate
cytosolic 85-kDa phospholipase A2 and subsequent
inhibition of arachidonic acid and prostaglandin synthesis by
cyclooxygenase in macrophages (Gewert and Sundler, 1995
). Indeed,
cyclooxygenase (COX) inhibitors, indomethacin and ibuprofen, partially
inhibited TNF-
induction of stromelysin mRNA.
Aspirin is an archetype of nonsteroidal anti-inflammatory drugs which
are commonly prescribed for the management of arthritis. Aspirin-like
drugs inhibit COX-2 induction by TNF-
and constitutive COX-1 (Geng
et al., 1995
), which through some unknown mechanism may inhibit
stromelysin gene expression observed here. Other nonsteroidal anti-inflammatory drugs such as Naproxen and Tenidap also inhibit collagenase mRNA expression in a canine model of arthritis (Fernandes et al., 1995
). Our results suggest that prostaglandins are partly involved in TNF-
induction of stromelysin. Alternatively, TNF-
could induce nitric oxide synthase (NOS) responsible for the synthesis of NO which could activate collagenase and stromelysin (Murrell et al.,
1995
). Aspirin-like drugs at pharmacological (1-3 mM) and
suprapharmacological (IC50 = 20 mM)
concentrations can inhibit inducible NOS (Amin et al., 1995
). Treatment
with NOS inhibitor, NMA, however, failed to block TNF-
action in our
system. A third possibility is that TNF-
-induced activation of
NF-
B and its translocation from cytoplasm to the nucleus is
inhibited by high doses of sodium salicylate and aspirin (Kopp and
Ghosh, 1994
) which some how influences stromelysin gene expression.
Activated NF-
B is commonly found in joints of OA and RA patients
(Marok et al., 1996
). AP-1 and polyoma virus enhancer A-binding protein 3- (PEA-3) (but not NF-
B) binding sites have been detected in the
known stromelysin promoters. An additional possibility is that at
higher concentrations, salicylate acted by its antioxidant type of
activity (Dinis et al., 1994
) and scavenged TNF-
-induced hydroxyl
radicals. This ability alone could be sufficient to inhibit stromelysin
induction by TNF-
.
Aspirin is an old wonder drug that reduces the risk of heart attacks
and colon cancer (Thun et al., 1991
). Aspirin and sodium salicylate
have neuroprotective abilities against glutamate toxicity by inhibiting
NF-
B activation (Grilli et al., 1996
). Stromelysin is involved in
arthritic cartilage erosion, instability of atherosclerotic plaques
(Galis et al., 1994
), and metastatic invasion of cancer cells. Our
demonstration of inhibition of stromelysin gene expression by
aspirin-like drugs suggests a possible beneficial effect of this drug
in these disorders and may explain the results of epidemiological studies on aspirin. Inhibition of TNF-
action is a major target for
suppressing inflammation. In experimentally induced arthritis in
rabbits, neutralization of TNF-
with its antibody suppressed inflammatory but not the cartilage resorptive aspect of arthritis, suggesting its key role in inflammation (Lewthwaite et al., 1995
). Our
study, utilizing stromelysin as a target, has demonstrated alternative
inhibitors of TNF-
action.
Inhibition of stromelysin mRNA induction by a reactive oxygen species
scavenger NAC suggests that reactive oxygen species are involved in
stromelysin induction by TNF-
. Oxidant by-products are used by
phagocytes to combat infections during immune response, but are also a
source of oxidative damage in degenerative diseases of aging (Ames et
al., 1993
). Indeed, a lower serum antioxidant level has been recognized
as a risk factor for rheumatoid arthritis (Heliövaara et al.,
1994
). Stromelysin mRNA inhibition by NAC may be a result of upstream
inhibition of redox-sensitive c-fos and c-jun transcription factor
expression by this antioxidant (Lo et al., 1996
). These AP-1 factors
along with PEA-3 binding factors are important regulators of the
transcription of human stromelysin promoter (Buttice et al., 1991
).
Other antioxidants such as
-tocopherol, ascorbate, and PDTC were not
inhibitory, but rather stimulatory (particularly PDTC), suggesting
distinct mechanisms of action for different antioxidants. This may be
due to the reported ability of PDTC to induce AP-1 transcription
factors whose targets are found in the stromelysin promoter (Yokoo and Kitamura, 1996
). Interestingly, induction of cartilage chondrolysis by
fibronectin fragments by MMPs is also inhibited by antioxidants (Homandberg et al., 1996
). NAC also blocks nuclear translocation of
NF-
B in rheumatoid synovial fibroblasts (Sakurada et al., 1996
).
In summary, we have demonstrated that stromelysin gene expression is
upregulated by TNF-
. Inhibition of this augmentation by
cycloheximide, glucocorticoids, salicylates, and NAC suggests that the
induction is mediated by de novo protein synthesis and intermediate
steps such as prostaglandins, reactive oxygen species, and AP-1, PEA-3,
or NF-
B transcription factor activation. These results also give a
better insight into the mechanism of action of these drugs, some of
which are benificial in the treatment of arthritis, cardiovascular
diseases, and cancer.
| |
Acknowledgments |
|---|
We are grateful to Dr. Richard Breathnach (Nantes, France) for the human stromelysin cDNA, Jean Maher (Abattoir les Cèdres) for supplying bovine joints, and Anna Chelchowska for preparing figures.
| |
Footnotes |
|---|
Accepted for publication January 19, 1999.
Received for publication October 2, 1997.
1 This work was supported by grants from the Medical Research Council of Canada (MT-12867), the Arthritis Society of Canada, and the Heart and Stroke Foundation of Quebec and a scholarship of the Fonds de la recherche en santé du Québec.
Send reprint requests to: Dr. M. Zafarullah, K-5255 Mailloux, CHUM Campus Notre-Dame, 1560 Sherbrooke est, Montréal, Québec, Canada H2L 4M1. E-mail: Zafarulm{at}ere.umontreal.ca
| |
Abbreviations |
|---|
AP-1, activator protein-1;
FCS, fetal calf
serum;
PEA-3, polyoma virus enhancer A-binding protein 3;
MMP, matrix
metalloproteinase;
NAC, N-acetylcysteine;
NMA, N-monomethyl-L-arginine;
PDTC, pyrrolidine
dithiocarbamate;
TIMP, tissue inhibitors of metalloproteinase;
TNF-
, tumor necrosis factor
.
| |
References |
|---|
|
|
|---|
precursor by metalloproteinases.
Nature (Lond)
370:
555-557[Medline].
B activation.
Science (Wash DC)
274:
1383-1385
B by sodium salicylate and aspirin.
Science (Wash DC)
265:
956-959
in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNF
neutralising monoclonal antibodies.
Ann Rheum Dis
54:
366-374
in mediation of immunosuppression by glucocorticoids.
Science (Wash DC)
270:
283-290
induces metalloproteinase mRNA expression in human fibroblasts. Role of activator protein-1.
J Biol Chem
269:
21627-21634
and dexamethasone in bovine and human articular chondrocytes.
DNA Cell Biol
15:
1039-1048[Medline].
stimulates AP-1 activity through prolonged activation of the c-Jun kinase.
J Biol Chem
269:
26396-26401This article has been cited by other articles:
![]() |
E. Candelario-Jalil, S. Taheri, Y. Yang, R. Sood, M. Grossetete, E. Y. Estrada, B. L. Fiebich, and G. A. Rosenberg Cyclooxygenase Inhibition Limits Blood-Brain Barrier Disruption following Intracerebral Injection of Tumor Necrosis Factor-{alpha} in the Rat J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 488 - 498. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Ulug, S. Goldman, I. Ben-Shlomo, and E. Shalev Matrix metalloproteinase (MMP)-2 and MMP-9 and their inhibitor, TIMP-1, in human term decidua and fetal membranes: the effect of prostaglandin F2{alpha} and indomethacin Mol. Hum. Reprod., December 1, 2001; 7(12): 1187 - 1193. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Gonzalez, D. L. Epstein, and T. Borrás Characterization of Gene Expression in Human Trabecular Meshwork Using Single-Pass Sequencing of 1060 Clones Invest. Ophthalmol. Vis. Sci., November 1, 2000; 41(12): 3678 - 3693. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||